TIBOLA : Multicenter Descriptive Study in Eastern France

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational

TIBOLA (TIck-BOrne LymphAdenopathy) is a tick-borne disease. The pathogen is most often rickettsia (R. slovaca or R. raoultii), but other strict intracellular bacteria have been described (Francisella tularensis, Coxiella burnetii, Bartonella hensenlae). Transmitted by ticks (Dermacentor), it is characterized by an inoculation eschar at the tick bite site, accompanied by painful loco-regional lymphadenopathy. It is most often a benign pathology, which can nevertheless leave sequellar alopecia or persistent asthenia. In spring 2021, an impression of increased cases was reported by clinicians in Eastern France. The study aims to clarify the clinical-biological presentation and the evolution of the number of cases of TIBOLA in this region between 2016 and 2021. At the same time, entomologists have noted an upsurge in this tick in certain biotopes in recent years.

Participation Requirements
Sex: All
Healthy Volunteers: No

• Person, minor or major,

• having been diagnosed with TIBOLA

• between January 1, 2016 and December 31, 2021

• at the University Hospital of Nancy or Strasbourg in the departments of infectious and tropical diseases, dermatology, microbiology and pediatrics.

Other Locations
Yves Hansmann
Elisabeth Baux
Time Frame
Start Date: June 1, 2022
Estimated Completion Date: June 1, 2023
Target number of participants: 20
Leads: Central Hospital, Nancy, France

This content was sourced from clinicaltrials.gov